Advisory Research Inc. Buys 9,880 Shares of AbbVie Inc. $ABBV

Advisory Research Inc. grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 16.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,001 shares of the company’s stock after purchasing an additional 9,880 shares during the quarter. AbbVie makes up about 2.1% of Advisory Research Inc.’s investment portfolio, making the stock its 16th largest position. Advisory Research Inc.’s holdings in AbbVie were worth $16,208,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter worth approximately $26,000. Caitlin John LLC purchased a new position in shares of AbbVie in the third quarter worth about $33,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at about $39,000. Finally, Redmont Wealth Advisors LLC purchased a new position in AbbVie in the 3rd quarter worth approximately $41,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

AbbVie stock opened at $225.36 on Friday. The firm has a market cap of $398.47 billion, a price-to-earnings ratio of 95.49, a PEG ratio of 0.79 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a fifty day simple moving average of $224.52 and a two-hundred day simple moving average of $224.48.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by corporate insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie advanced a risankizumab dosing Phase 1 study, signaling continued investment in immunology R&D that supports long‑term growth expectations. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: AbbVie’s ABBV‑295 reported encouraging Phase 1 results, adding to near‑term pipeline optionality that could drive upside if later‑stage data hold. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: RBC Capital initiated coverage with an Outperform and $260 target, reflecting bullish analyst conviction around Skyrizi/Rinvoq rollout and immunology growth potential. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Neutral Sentiment: Analyst fair‑value models moved only slightly and views are split — some see upside from immunology, others flag competition risk, leaving headline price targets largely unchanged. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Market research highlights expanding opportunities in indications like bipolar depression over the coming decade, a long‑term tailwind but not an immediate catalyst. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Competitive setback: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis data, raising market‑share and pricing risk for a key immunology franchise. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Reported insider selling drew negative attention and was cited as a near‑term headwind to sentiment and share price. AbbVie (NYSE:ABBV) Stock Price Down 1% on Insider Selling

Analysts Set New Price Targets

Several equities research analysts have weighed in on ABBV shares. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Scotiabank initiated coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Morgan Stanley boosted their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.